Waters Corporation announced an agreement with the Chinese Pharmacopoeia Commission (ChP) to establish a joint open laboratory. Scheduled to open before the end of 2014, the new joint open laboratory will focus on in-depth research of pharmacopoeia standards, development of testing methods, methods validations and basic and advanced technical training of pharmacopoeia detection methods. Both ChP and Waters expect the laboratory to become one of the national technical support centres in the field of Chinese pharmaceutical standards.
“Waters is excited about our new collaboration with the Chinese Pharmacopeia Commission,” said Art Caputo, President, Waters Division. “I am confident that this new joint open laboratory will make positive contributions to assuring drug quality control in China, it will quickly become an international leader in the field of traditional Chinese pharma standards.”
At the collaboration agreement signing ceremony in Beijing, Secretary General Zhang Wei of the ChP pointed out that “the ChP-Waters Joint Open Laboratory cooperation would become another milestone of the development of the ChP. This cooperation not only meets the needs of ChP’s own development, but also meets the demands of enhanced pharmacopoeia standards and improved public drug safety.”
Located in the laboratory building of Beijing Zhendong Guangming Drug Research Institute, the new joint open laboratory is more than 400 square metres (more than 1300 square feet). The laboratory will be outfitted with a full complement of Waters chromatography and mass spectrometry technologies, including (but not limited to) a range of ACQUITY UPLC systems, ACQUITY UPC2 System, Xevo tandem quadrupole and time-of-flight mass spectrometers, and a Natural Products Application Solution with UNIFI.
EP News Bureau – Mumbai